Effects of serum and autologous conditioned serum on equine articular chondrocytes treated with interleukin-1 β

Eric R. Carlson Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.

Search for other papers by Eric R. Carlson in
Current site
Google Scholar
PubMed
Close
 DVM
,
Allison A. Stewart Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.

Search for other papers by Allison A. Stewart in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Kelly L. Carlson Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.

Search for other papers by Kelly L. Carlson in
Current site
Google Scholar
PubMed
Close
 DVM
,
Sushmitha S. Durgam Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.

Search for other papers by Sushmitha S. Durgam in
Current site
Google Scholar
PubMed
Close
 DVM, MS
, and
Holly C. Pondenis Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.

Search for other papers by Holly C. Pondenis in
Current site
Google Scholar
PubMed
Close
 BS

Abstract

Objective—To compare the effects of autologous equine serum (AES) and autologous conditioned serum (ACS) on equine articular chondrocyte metabolism when stimulated with recombinant human (rh) interleukin (IL)-1β.

Sample—Articular cartilage and nonconditioned and conditioned serum from 6 young adult horses.

Procedures—Cartilage samples were digested, and chondrocytes were isolated and formed into pellets. Chondrocyte pellets were treated with each of the following: 10% AES, 10% AES and rhIL-1β, 20% AES and rhIL-1β, 10% ACS and rhIL-1β, and 20% ACS and rhIL-1β, and various effects of these treatments were measured.

Results—Recombinant human IL-1β treatment led to a decrease in chondrocyte glycosaminoglycan synthesis and collagen II mRNA expression and an increase in medium matrix metalloproteinase-3 activity and cyclooxygenase-2 mRNA expression. When results of ACS and rhIL-1β treatment were compared with those of AES and rhIL-1β treatment, no difference was evident in glycosaminoglycan release, total glycosaminoglycan concentration, total DNA content, or matrix metalloproteinase-3 activity. A significant increase was found in chondrocyte glycosaminoglycan synthesis with 20% AES and rhIL-1β versus 10% ACS and rhIL-1β. The medium from ACS and rhIL-1β treatment had a higher concentration of IL-1β receptor antagonist, compared with medium from AES and rhIL-1β treatment. Treatment with 20% ACS and rhIL-1β resulted in a higher medium insulin-like growth factor-I concentration than did treatment with 10% AES and rhIL-1β. No difference in mRNA expression was found between ACS and rhIL-1β treatment and AES and rhIL-1β treatment.

Conclusions and Clinical Relevance—Minimal beneficial effects of ACS treatment on proteoglycan matrix metabolism in equine chonrocytes were evident, compared with the effects of AES treatment.

Abstract

Objective—To compare the effects of autologous equine serum (AES) and autologous conditioned serum (ACS) on equine articular chondrocyte metabolism when stimulated with recombinant human (rh) interleukin (IL)-1β.

Sample—Articular cartilage and nonconditioned and conditioned serum from 6 young adult horses.

Procedures—Cartilage samples were digested, and chondrocytes were isolated and formed into pellets. Chondrocyte pellets were treated with each of the following: 10% AES, 10% AES and rhIL-1β, 20% AES and rhIL-1β, 10% ACS and rhIL-1β, and 20% ACS and rhIL-1β, and various effects of these treatments were measured.

Results—Recombinant human IL-1β treatment led to a decrease in chondrocyte glycosaminoglycan synthesis and collagen II mRNA expression and an increase in medium matrix metalloproteinase-3 activity and cyclooxygenase-2 mRNA expression. When results of ACS and rhIL-1β treatment were compared with those of AES and rhIL-1β treatment, no difference was evident in glycosaminoglycan release, total glycosaminoglycan concentration, total DNA content, or matrix metalloproteinase-3 activity. A significant increase was found in chondrocyte glycosaminoglycan synthesis with 20% AES and rhIL-1β versus 10% ACS and rhIL-1β. The medium from ACS and rhIL-1β treatment had a higher concentration of IL-1β receptor antagonist, compared with medium from AES and rhIL-1β treatment. Treatment with 20% ACS and rhIL-1β resulted in a higher medium insulin-like growth factor-I concentration than did treatment with 10% AES and rhIL-1β. No difference in mRNA expression was found between ACS and rhIL-1β treatment and AES and rhIL-1β treatment.

Conclusions and Clinical Relevance—Minimal beneficial effects of ACS treatment on proteoglycan matrix metabolism in equine chonrocytes were evident, compared with the effects of AES treatment.

Contributor Notes

Supported by the Brinker Resident Research Award through the Veterinary Orthopedic Research Society.

Presented in abstract form at the American College of Veterinary Surgeons Forum, Chicago, November 2011.

Address correspondence to Dr. Stewart (aaw@illinois.edu).
  • 1. USDA APHIS Veterinary Services National Health Monitoring System. National economic cost of equine lameness, colic, and equine protozoal myeloencephalitis in the United States. Information Sheet. No. N348.1001. Fort Collins, Colo: USDA APHIS Veterinary Services National Health Monitoring System, 2001.

    • Search Google Scholar
    • Export Citation
  • 2. Jeffcott LB, Rossdale PD, Freestone J, et al. An assessment of wastage in Thoroughbred racing from conception to 4 years of age. Equine Vet J 1982; 14:185198.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3. Rossdale PD, Hopes R, Digby NJ, et al. Epidemiological study of wastage among racehorses 1982 and 1983. Vet Rec 1985; 116:6669.

  • 4. Neundorf RH, Lowerison MB, Cruz AM, et al. Determination of the prevalence and severity of metacarpophalangeal joint osteoarthritis in Thoroughbred racehorses via quantitative macroscopic evaluation. Am J Vet Res 2010; 71:12841293.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5. Jackman BR. Common lameness in the cutting and reining horse, in Proceedings. 51st Annu Conv Am Assoc Equine Pract 2001;611.

  • 6. Joek N. Lameness in the western pleasure horses, in Proceedings. 51st Annu Conv Am Assoc Equine Pract 2001;1214.

  • 7. Smith RL, Allison AC, Schurman DJ. Induction of articular cartilage degradation by recombinant interleukin 1 alpha and 1 beta. Connect Tissue Res 1989; 18:307316.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8. Meijer H, Reinecke J, Becker C, et al. The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. Inflammation Res 2003; 52:404407.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9. Malyak M, Swaney RE, Arend WP. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils. Arthritis Rheum 1993; 36:781789.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10. Martel-Pelletier J, Pelletier JP. Importance of interleukin-I receptors in osteoarthritis [in French]. Rev Rhum Ed Fr 1994; 61:109113.

    • Search Google Scholar
    • Export Citation
  • 11. Frisbie DD, Kawcak CE, Werpy NM, et al. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007; 68:290296.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12. Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996; 39:15351544.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13. Stove J, Huch K, Gunther KP, et al. Interleukin-1beta induces different gene expression of stromelysin, aggrecan and tumor-necrosis-factor-stimulated gene 6 in human osteoarthritic chondrocytes in vitro. Pathobiology 2000; 68:144149.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14. Goldring MB, Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res 2004; 427 (suppl):S37S46.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15. Frisbie DD, Ghivizzani SC, Robbins PD, et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9:1220.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16. Hraha TH, Doremus KM, McIlwraith CW, et al. Autologous conditioned serum: the comparative cytokine profiles of two commercial methods (IRAP and IRAP II) using equine blood. Equine Vet J 2011; 43:516521.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17. Schaefer EC, Stewart AA, Durgam SS, et al. Effects of sodium hyaluronate and triamcinolone acetonide on glucosaminoglycan metabolism in equine articular chondrocytes treated with interleukin-1. Am J Vet Res 2009; 70:14941501.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18. Masuda K, Shirota H, Thonar EJ. Quantification of 35S-labeled proteoglycans complexed to alcian blue by rapid filtration in multiwell plates. Anal Biochem 1994; 217:167175.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19. Farndale RW, Sayers CA, Barrett AJ. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res 1982; 9:247248.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20. Kim YJ, Sah RL, Doong JY, et al. Fluorometric assay of DNA in cartilage explants using Hoechst 33258. Anal Biochem 1988; 174:168176.

  • 21. Grodzinsky AJ, Levenston ME, Jin M, et al. Cartilage tissue remodeling in response to mechanical forces. Annual Rev Biomed Eng 2000; 2:691713.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22. Richardson DW, Dodge GR. Dose-dependent effects of corticosteroids on the expression of matrix-related genes in normal and cytokine-treated articular chondrocytes. Inflamm Res 2003;52:3949.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23. Koller MR, Maher RJ, Manchel I, et al. Alternatives to animal sera for human bone marrow cell expansion: human serum and serum-free media. J Hematother 1998; 7:413423.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24. Rutgers M, Saris DB, Dhert WJ, et al. Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection. Arthritis Res Ther 2010; 12:R114.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25. Naito K, Takahashi M, Kushida K, et al. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis. Rheumatol (Oxford) 1999; 38:510515.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26. Wang X, Li F, Fan C, et al. Effects and relationship of ERK1 and ERK2 in interleukin-1B-induced alterations in MMP3, MMP13, type II collagen and aggrecan expression in human chondrocytes. Int J Mol Med 2011; 27:583589.

    • Search Google Scholar
    • Export Citation
  • 27. Ekenstedt KJ, Sonntag WE, Loeser RF, et al. Effects of chronic growth hormone and insulin-like growth factor 1 deficiency on osteoarthritis severity in rat knee joints. Arthritis Rheum 2006; 54:38503858.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28. Fortier LA, Barker JU, Strauss EJ, et al. The role of growth factors in cartilage repair. Clin Orthop Relat Res 2011; 469:27062715.

Advertisement